141 related articles for article (PubMed ID: 33652898)
1. Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.
Naipaul RD; Mercer RE; Chan KKW; Yeung L; Forbes L; Gavura S
Curr Oncol; 2021 Feb; 28(2):1056-1066. PubMed ID: 33652898
[TBL] [Abstract][Full Text] [Related]
2. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
Berry SR; Hubay S; Soibelman H; Martin DK
BMC Health Serv Res; 2007 Nov; 7():193. PubMed ID: 18042302
[TBL] [Abstract][Full Text] [Related]
3. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
[TBL] [Abstract][Full Text] [Related]
4. Impact of a novel prioritization framework on clinician-led oncology drug submissions.
Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S
Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821
[TBL] [Abstract][Full Text] [Related]
5. A cross-sectional survey assessing the preparedness of the long-term care sector to respond to the COVID-19 pandemic in Ontario, Canada.
Siu HY; Kristof L; Elston D; Hafid A; Mather F
BMC Geriatr; 2020 Oct; 20(1):421. PubMed ID: 33092541
[TBL] [Abstract][Full Text] [Related]
6. Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19.
Berlin A; Lovas M; Truong T; Melwani S; Liu J; Liu ZA; Badzynski A; Carpenter MB; Virtanen C; Morley L; Bhattacharyya O; Escaf M; Moody L; Goldfarb A; Brzozowski L; Cafazzo J; Chua MLK; Stewart AK; Krzyzanowska MK
JAMA Oncol; 2021 Apr; 7(4):597-602. PubMed ID: 33410867
[TBL] [Abstract][Full Text] [Related]
7. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
Daroudi R; Mirzania M; Zendehdel K
Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
[TBL] [Abstract][Full Text] [Related]
8. Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives.
Loree JM; Dau H; Rebić N; Howren A; Gastonguay L; McTaggart-Cowan H; Gill S; Raghav K; De Vera MA
Curr Oncol; 2021 Jan; 28(1):671-677. PubMed ID: 33499380
[TBL] [Abstract][Full Text] [Related]
9. Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic.
Tsagakis I; Papatriantafyllou M
Mol Oncol; 2020 Dec; 14(12):2987-2993. PubMed ID: 33128324
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on Cost and Value in Cancer Care.
Saltz LB
JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
[No Abstract] [Full Text] [Related]
11. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
Raymakers AJN; Regier DA; Peacock SJ
Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
[TBL] [Abstract][Full Text] [Related]
13. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective.
de Joode K; Dumoulin DW; Engelen V; Bloemendal HJ; Verheij M; van Laarhoven HWM; Dingemans IH; Dingemans AC; van der Veldt AAM
Eur J Cancer; 2020 Sep; 136():132-139. PubMed ID: 32683273
[TBL] [Abstract][Full Text] [Related]
14. US Cancer Care System Ill-Equipped to Deliver New Advances to Patients.
Rappaport M
J Oncol Pract; 2016 May; 12(5):397. PubMed ID: 27170686
[No Abstract] [Full Text] [Related]
15. How Australian Health Care Services Adapted to Telehealth During the COVID-19 Pandemic: A Survey of Telehealth Professionals.
Taylor A; Caffery LJ; Gesesew HA; King A; Bassal AR; Ford K; Kealey J; Maeder A; McGuirk M; Parkes D; Ward PR
Front Public Health; 2021; 9():648009. PubMed ID: 33718325
[No Abstract] [Full Text] [Related]
16. Patient and clinician experience with a rapidly implemented large-scale video consultation program during COVID-19.
Barkai G; Gadot M; Amir H; Menashe M; Shvimer-Rothschild L; Zimlichman E
Int J Qual Health Care; 2021 Feb; 33(1):. PubMed ID: 33313891
[TBL] [Abstract][Full Text] [Related]
17. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
18. An urgent call to raise the bar in oncology.
Schnog JB; Samson MJ; Gans ROB; Duits AJ
Br J Cancer; 2021 Nov; 125(11):1477-1485. PubMed ID: 34400802
[TBL] [Abstract][Full Text] [Related]
19. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
20. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
